20 December 2024 - Today, the US FDA approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnoea in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity.

Zepbound’s approval for moderate to severe obstructive sleep apnoea in adults with obesity is based on two randomised, double-blind, placebo-controlled studies of 469 adults without type 2 diabetes.

Read FDA press release